NEW YORK (360Dx) – T2 Biosystems announced on Tuesday that it has begun a public offering of 5.657 million shares of its common stock.

T2 Bio has not yet priced its shares. It said that it will grant the underwriters a 30-day option to purchase up to an additional 847,500 shares of its common stock.

Leerink Partners will act as joint book-running manager for the offering, while Canaccord Genuity will act as passive book-running manager. In addition, Janney Montgomery Scott, JonesTrading Services, and WBB Securities will act as co-managers for the offering.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 


In this webinar, Dr. Matthew Faron, a pathologist from the Medical College of Wisconsin, will share results of a comparison study of three rapid influenza assays.


Sponsored by

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.